Differences in retinal neovascular tissue and vitreous humour in patients with type 1 and type 2 diabetes

British Journal of Ophthalmology

Volumn 93, Issue 8, 2009, Pages 1109-1115

  Kinnunen, K ^a,b   Puustjarvi T ^a,b   Terasvirta M ^a,b   Nurmenniemi, P ^a,b   Heikura, T ^b   Laidinen, S ^b   Paavonen, T ^c   Uusitalo, H ^b,c,d   Yla Herttuala S ^a,b  

^a KUOPIO UNIVERSITY HOSPITAL   (Finland)

^b UNIVERSITY OF EASTERN FINLAND   (Finland)

^c TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^d TAMPERE UNIVERSITY HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPOIETIN 2; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; VASCULOTROPIN A; VASCULOTROPIN D;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INFLAMMATION; INSULIN DEPENDENT DIABETES MELLITUS; MALE; NEOVASCULARIZATION (PATHOLOGY); NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROLIFERATIVE RETINOPATHY; RETINA MACULA HOLE; TREATMENT OUTCOME; VITREOUS BODY;

ADULT; AGED; ANGIOGENESIS INDUCING AGENTS; ANGIOPOIETIN-1; ANGIOPOIETIN-2; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIABETIC RETINOPATHY; FEMALE; HUMANS; MALE; MIDDLE AGED; RETINAL NEOVASCULARIZATION; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR D; VITREOUS BODY;

EID: 68049089633     PISSN: 00071161     EISSN: 14682079     Source Type: Journal    
DOI: 10.1136/bjo.2008.148841     Document Type: Article

References (22)

1. Enge M, Bjarnegard M, Gerhardt H, et al. Endothelium-specific platelet-derived growth factor-B ablation mimics diabetic retinopathy. EMBO J 2002;21:4307-4316 (Pubitemid 34898182)
2. Aiello LP, Avery RL, Arrigg PG, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 1994;331:1480-1487
3. Ferrara N, Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr Rev 1997;18:4-25. (Pubitemid 27076453)
4. Reichelt M, Shi S, Hayes M, et al. Vascular endothelial growth factor-B and retinal vascular development in the mouse. Clin Experiment Ophthalmol 2003;31:61-65 (Pubitemid 36322002)
5. Achen M, Jeltsch M, Kukk E, et al. Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4). Proc Natl Acad Sci U S A 1998;95:548-553
6. Stacker SA, Stenvers K, Caesar C, et al. Biosynthesis of vascular endothelial growth factor-d involves proteolytic processing which generates non-covalent homodimers. J Biol Chem 1999;274:32127-32136 (Pubitemid 129503808)
7. Marconcini L, Marchiò S, Morbidelli L, et al. c-fos-Induced growth factor/vascular endothelial growth factor D induces angiogenesis in vivo and in vitro. Proc Natl Acad Sci U S A 1999;96:9671-9676 (Pubitemid 29398790)
8. Stacker SA, Caesar C, Baldwin ME, et al. VEGF-D promotes the metastatic spread of tumor cells via the lymphatics. Nat Med 2001;7:186-191 (Pubitemid 32148485)
9. Achen MG, Williams RA, Minekus MP, et al. Localization of vascular endothelial growth factor-D in malignant melanoma suggests a role in tumour angiogenesis. J Pathol 2001;193:147-154
10. Rutanen J, Leppanen P, Tuomisto TT, et al. Vascular endothelial growth factor-D expression in human atherosclerotic lesions. Cardiovasc Res 2003;59:971-979 (Pubitemid 38366253)
11. Yla-Herttuala S, Lipton BA, Rosenfeld ME, et al. Expression of monocyte chemoattractant protein 1 in macrophage-rich areas of human and rabbit atherosclerotic lesions. Proc Natl Acad Sci U S A 1991;88:5252-5256 (Pubitemid 21914722)
12. Rissanen TT, Markkanen JE, Gruchala M, et al. VEGF-D is the strongest angiogenic and lymphangiogenic effector among VEGFs delivered into skeletal muscle via adenoviruses. Circ Res 2003;92:1098-1106 (Pubitemid 36665855)
13. Kinnunen K, Korpisalo P, Rissanen TT, et al. Overexpression of VEGF-A induces neovascularization and increased vascular leakage in rabbit eye after intravitreal adenoviral gene transfer. Acta Physiol 2006;187:447-457
14. Henricsson M, Nilsson A, Groop L, et al. Prevalence of diabetic retinopathy in relation to age at onset of the diabetes, treatment, duration and glycemic control. Acta Ophthalmol Scand 1996;74:523-527 (Pubitemid 27042670)
15. Klein R, Klein BE, Moss SE, et al. The Wisconsin epidemiologic study of diabetic retinopathy. IV. Diabetic macular edema. Ophthalmology 1984;91:1464-1474
16. Jia H, Bagherzadeh A, Bicknell R, et al. Vascular endothelial growth factor (VEGF)-D and VEGF-A differentially regulate KDR-mediated signaling and biological function in vascular endothelial cells. J Biol Chem 2004;279:36148-36157 (Pubitemid 39100623)
17. Ikeda Y, Yonemitsu Y, Onimaru M, et al. The regulation of vascular endothelial growth factors (VEGF-A, -C, and -D) expression in the retinal pigment epithelium. Exp Eye Res 2006;83:1031-1040 (Pubitemid 44397024)
18. Tooke JE. Possible pathophysiological mechanisms for diabetic angiopathy in type 2 diabetes. J Diabetes Complicat 2000;14:197-200.
19. Cursiefen C, Chen L, Borges LP, et al. VEGF-A stimulates lymphangiogenesis and hemangiogenesis in inflammatory neovascularization via macrophage recruitment. J Clin Invest 2004;113:1040-1050 (Pubitemid 38544126)
20. Witmer AN, Blaauwgeers HG, Weich HA, et al. Altered expression patterns of VEGF receptors in human diabetic retina and in experimental VEGF-induced retinopathy in monkey. Invest Ophthalmol Vis Sci 2002;43:849-857
21. Watanabe D, Suzuma K, Suzuma I, et al. Vitreous levels of angiopoietin 2 and vascular endothelial growth factor in patients with proliferative diabetic retinopathy. Am J Ophthalmol 2005;139:476-481 (Pubitemid 40379074)
22. Abu El-Asrar AM, Missotten L, Geboes K. Expression of hypoxia-inducible factor-1α and the protein products of its target genes in diabetic fibrovascular epiretinal membranes. Br J Ophthalmol 2007;91:822-826 (Pubitemid 46846660)